Tags

Type your tag names separated by a space and hit enter

Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.
Br J Cancer. 1993 Feb; 67(2):237-43.BJ

Abstract

A new cancer-associated antigen CA130, recognised by two monoclonal antibodies (moABs) 130-22 and 145-9, was often found to be present at high levels in the sera of patients with ovarian cancer. There was a strong correlation between CA130 and CA125 values. The epitopes recognised by moABs 130-22 and 145-9 were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. Unlike OC125, the majority of 130-22/145-9 activity was associated with a much lower molecular mass (less than 200 kDa), indicating that a lower molecular mass immunoreactive determination may be a unique CA130 antigenic determinant within CA125 molecule. Clinical data demonstrate that, (1) elevated levels of CA130 determinant were found in the sera of 91.3% of women with epithelial ovarian cancer, (2) falling or rising levels of CA130 correlated with regression or progression of ovarian cancer in > 95% of cases, (3) normalisation of serum CA130 levels at response does not imply no microscopic residual disease, but CA130 changes during follow-up support the evaluation of recurrence and can be used as a monitoring marker in an individual patient.

Authors+Show Affiliations

Department of Obstetrics and Gynaecology, Hamamatsu University School of Medicine, Shizuoka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

7679280

Citation

Kobayashi, H, et al. "Characterisation and Clinical Usefulness of CA130 Antigen Recognised By Monoclonal Antibodies, 130-22 and 145-9, in Ovarian Cancers." British Journal of Cancer, vol. 67, no. 2, 1993, pp. 237-43.
Kobayashi H, Ohi H, Fujii T, et al. Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers. Br J Cancer. 1993;67(2):237-43.
Kobayashi, H., Ohi, H., Fujii, T., & Terao, T. (1993). Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers. British Journal of Cancer, 67(2), 237-43.
Kobayashi H, et al. Characterisation and Clinical Usefulness of CA130 Antigen Recognised By Monoclonal Antibodies, 130-22 and 145-9, in Ovarian Cancers. Br J Cancer. 1993;67(2):237-43. PubMed PMID: 7679280.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers. AU - Kobayashi,H, AU - Ohi,H, AU - Fujii,T, AU - Terao,T, PY - 1993/2/1/pubmed PY - 1993/2/1/medline PY - 1993/2/1/entrez SP - 237 EP - 43 JF - British journal of cancer JO - Br J Cancer VL - 67 IS - 2 N2 - A new cancer-associated antigen CA130, recognised by two monoclonal antibodies (moABs) 130-22 and 145-9, was often found to be present at high levels in the sera of patients with ovarian cancer. There was a strong correlation between CA130 and CA125 values. The epitopes recognised by moABs 130-22 and 145-9 were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. Unlike OC125, the majority of 130-22/145-9 activity was associated with a much lower molecular mass (less than 200 kDa), indicating that a lower molecular mass immunoreactive determination may be a unique CA130 antigenic determinant within CA125 molecule. Clinical data demonstrate that, (1) elevated levels of CA130 determinant were found in the sera of 91.3% of women with epithelial ovarian cancer, (2) falling or rising levels of CA130 correlated with regression or progression of ovarian cancer in > 95% of cases, (3) normalisation of serum CA130 levels at response does not imply no microscopic residual disease, but CA130 changes during follow-up support the evaluation of recurrence and can be used as a monitoring marker in an individual patient. SN - 0007-0920 UR - https://www.unboundmedicine.com/medline/citation/7679280/Characterisation_and_clinical_usefulness_of_CA130_antigen_recognised_by_monoclonal_antibodies_130_22_and_145_9_in_ovarian_cancers_ L2 - https://doi.org/10.1038/bjc.1993.46 DB - PRIME DP - Unbound Medicine ER -